Status:
TERMINATED
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Breast Neoplasms
Neoplasm Metastasis
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-...
Eligibility Criteria
Inclusion
- Women aged greater than 18 years.
- Postmenopausal subjects
- Confirmed diagnosis of locally advanced (not amenable to curative surgery and/or radiation) or metastatic breast cancer (Stage 3B or 4 respectively, by American Joint Committee on Cancer Criteria)
Exclusion
- Extensive visceral disease
- Subjects with bone as the only site of disease
- Prior radiation therapy to the site of measurable disease for subjects with a solitary measurable lesion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
1236 Patients enrolled
Trial Details
Trial ID
NCT00083993
Start Date
May 1 2004
End Date
October 1 2006
Last Update
November 8 2011
Active Locations (129)
Enter a location and click search to find clinical trials sorted by distance.
1
Hoover, Alabama, United States, 35216
2
Huntsville, Alabama, United States, 35801
3
Tucson, Arizona, United States, 85715
4
Jonesboro, Arkansas, United States, 72401